AVDL News and Press, Avadel Pharmaceuticals plc From 07/07/21

DUBLIN, Ireland, July 07, 2021 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate for treating excessive daytime sleepiness and cataplexy in adults with narcolepsy, announced to...

Avadel Pharmaceuticals ([[AVDL]]) announces new post hoc analyses of data from Phase 3 REST-ON trial of FT218. FT218 is currently under FDA review with PDUFA target date of October 15, 2021. Highlights from the poster presentations are outlined below. Efficacy of FT218 by Narcolepsy Subt...

Data show improvement in excessive daytime sleepiness for both narcolepsy subtypes and with and without stimulant use; demonstrate decreases in weight and body mass index Post hoc analyses further support positive primary and secondary endpoint data for all evaluated doses of ...

DUBLIN, Ireland, June 03, 2021 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate for treating excessive daytime sleepiness and cataplexy in adults with narcolepsy, today announ...

The following slide deck was published by Avadel Pharmaceuticals plc in conjunction with this event. For further details see: Avadel Pharmaceuticals (AVDL) Investor Presentation - Slideshow

Healthcare faces an important decision as the Supreme Court decides on the Affordable Care Act. Biotechs face an important FDA decision on approval of an Alzheimer's treatment. Oncology companies get ready to present new data at the largest US oncology conference with potential fo...

DUBLIN, Ireland, June 02, 2021 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate for treating excessive daytime sleepiness and cataplexy in adults with narcolepsy, announced to...

DUBLIN, Ireland, May 25, 2021 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate for treating excessive daytime sleepiness and cataplexy in adults with narcolepsy, announced tod...

AVDL’s once-nightly controlled release formulation of sodium oxybate (FT218) for narcolepsy addresses a key liability in the leading drug, Xyrem, which requires a second dose during the night. The FDA accepted the NDA for FT218 in March 2021 and set a PDUFA date of Oct 15. ...

Yesterday, Jazz Pharmaceuticals (JAZZ) filed a complaint in Delaware federal court against Avadel Pharmaceuticals (AVDL) regarding an alleged infringement of five patents linked to the company’s blockbuster therapy Xyrem.The FDA application sought by Avadel to market its narcolepsy dru...